Welcome to Tech Beat, your daily read on the technology stories that matter.
SpaceX made its long-awaited debut on the Nasdaq today, and the headlines are pulling in two directions. The company has reserved an unusually generous slice of shares for everyday investors, but analysts are tempering expectations fast — retail buyers, they warn, are largely getting the leftovers. Meanwhile, Elon Musk's near-absolute control over the company is drawing sharp scrutiny from market watchers who question whether that kind of concentrated power belongs in a publicly traded structure. SpaceX has always operated this way, but now the whole market gets a vote.
Shifting to a story about the fragility underneath our digital economy — a new analysis from TechRadar is sounding the alarm on cloud resilience, or rather the lack of it. Businesses of every size have built their operations on a handful of cloud providers, but most have done very little to prepare for the moment those providers go dark. The argument is straightforward: dependency this deep demands a backup plan, and most organizations simply do not have one.
And in science that sits at the edge of technology and medicine, MIT Technology Review is exploring cellular reprogramming as a serious contender in the race to reverse aging. Life Biosciences this week dosed its first human volunteer, injecting an experimental treatment directly into the eye of a patient with glaucoma, hoping to regenerate damaged nerves entirely.
Keep surfing. Tech Beat out.
